2,3-Dehydrosilybin A/B as a pro-longevity and anti-aggregation compound

Area of Science:

• Gerontology
• Molecular Biology
• Neuroscience

Background:

• Aging is a primary risk factor for age-related diseases, driven by homeostatic failure.
• Natural compounds with anti-aging, anti-aggregation, and anti-oxidation properties are sought for dietary intervention.
• Silymarin, a plant extract, contains various compounds with potential health benefits.

Purpose of the Study:

• To investigate the anti-aging and anti-aggregation effects of 2,3-dehydrosilybin A/B (DHS A/B), a silymarin component.
• To determine the molecular pathways involved in DHS A/B's effects.
• To evaluate DHS A/B as a potential therapeutic agent for aging and neurodegenerative diseases.

Main Methods:

• Assessed oxidative stress resistance in human primary cells and Caenorhabditis elegans (C. elegans) models.
• Measured lifespan extension in C. elegans treated with DHS A/B.
• Investigated protein aggregation in human neuronal cells and C. elegans models of Alzheimer's disease (AD).
• Utilized genetic analysis to identify key molecular pathways (FGT-1 and DAF-16).

Main Results:

• DHS A/B conferred significant oxidative stress resistance in both human cells and C. elegans.
• DHS A/B promoted lifespan extension in C. elegans, dependent on FGT-1 and DAF-16 pathways.
• DHS A/B demonstrated anti-aggregation properties in human neuronal cells and ameliorated AD phenotypes in nematode models.
• Identified DHS A/B as the active component responsible for silymarin's anti-aging and anti-aggregation effects.

Conclusions:

• DHS A/B exhibits potent anti-aging properties, including oxidative stress resistance and lifespan extension.
• DHS A/B effectively reduces protein aggregation, suggesting therapeutic potential for Alzheimer's disease.
• DHS A/B is identified as a key active compound in silymarin, warranting further investigation as a dietary anti-aging and anti-aggregation agent.